Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

A, Ghavamzadeh; K, Alimoghaddam; S, Rostami; SH, Ghaffari; M, Jahani; M, Iravani; SA, Mousavi; B, Bahar; M, Jalili

doi:10.1200/jco.2010.32.2107

Public

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

Shared by NobleBlocks on Jun 6, 2011 • 12:00 AM UTC

Authors:

Ghavamzadeh A

Alimoghaddam K

Rostami S

Abstract

<h4>Purpose</h4>The long-term follow-up results of patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid and chemotherapy show high cure rates. Several studies have shown high efficacy of single-agent arsenic trioxide in newly diagnosed APL. However, long-term follow-...

Discussions